烟酰胺治疗早期阿尔茨海默病的2A期概念验证双盲随机安慰剂对照试验
这项2A期概念验证双盲随机安慰剂对照试验在2个学术临床中心纳入47例经脑脊液生物标志物确诊的早期阿尔茨海默病(AD)患者,评估每日3000 mg烟酰胺治疗48周的安全性和耐受性。主要结局脑脊液p-tau231变化无统计学显著获益,次要生物标志物亦无显著效应;CDR-SB显示烟酰胺组下降较少(未校正多重比较)。结论认为烟酰胺安全但未改变AD生物标志物。
要点
- 烟酰胺每日3000 mg治疗48周安全,不良事件两组均衡,归因于治疗者少。
- 主要结局脑脊液p-tau231变化无统计学显著获益(估计均值差-2.06,SE 4.03;p=0.61)。
- CDR-SB第48周烟酰胺组下降较少(估计值-1.42,SE 0.65;p=0.03,未校正多重比较)。
核心结论
- 烟酰胺安全但未改变AD生物标志物;在脑脊液AD生物标志物阳性的轻度认知障碍或轻度痴呆患者中,每日3000 mg烟酰胺治疗48周在降低脑脊液p-tau231方面不优于安慰剂(Class I证据)。
研究设计与样本
- 随机、安慰剂对照、2A期概念验证试验,评估每日两次每次1500 mg烟酰胺治疗48周的安全性和耐受性。
- 在2个学术临床中心招募47例经脑脊液生物标志物确诊AD的轻度认知障碍或轻度痴呆患者(平均年龄73.8岁;女性43%)。
- 主要结局为脑脊液p-tau231水平;预设次要结局包括脑脊液p-tau181、总tau、Aβ40、Aβ42及ADAS-cog13、ADCS-ADL-MCI、CDR-SB临床量表;采用Holm-Bonferroni法在生物标志物和临床领域内控制I类错误。
主要发现
- 47例入组者中,治疗开始前退出1例,完成前退出6例(烟酰胺组2例,安慰剂组4例)。
- 不良事件按组均衡,归因于治疗者少;常见不良事件包括感染和神经系统疾病。
- 主要结局第48周脑脊液p-tau231较基线变化无统计学显著获益(协方差分析;组间变化估计均值差=-2.06,SE=4.03;p=0.61),观察到的脑脊液p-tau231平均下降在烟酰胺组(-4.7±14.5)大于安慰剂组(-2.3±10.6)。
- 次要生物标志物结局(脑脊液p-tau181、Aβ40、Aβ42和总tau)在类似模型中均无显著治疗效应(所有p值>0.05);观察到的脑脊液p-tau181变化(烟酰胺组0.4±29.8 vs 安慰剂组10.4±41.8)和总tau变化(烟酰胺组8.4±228.6 vs 安慰剂组60.5±237.5)偏向烟酰胺。
- 第48周时,烟酰胺组CDR-SB下降较少(重复测量混合效应模型;估计值=-1.42,SE=0.65;未校正多重比较p=0.03),认知(ADAS-cog;估计值=-1.93,SE=1.93;p=0.32)和功能(ADCS-ADL-MCI;估计值=-3.10,SE=1.86;p=0.10)结局无显著差异。
关键数值与推荐
- 主要结局脑脊液p-tau231第48周较基线变化:组间估计均值差=-2.06,SE=4.03;p=0.61。
- CDR-SB第48周:估计值=-1.42,SE=0.65;未校正多重比较p=0.03。
- ADAS-cog:估计值=-1.93,SE=1.93;p=0.32;ADCS-ADL-MCI:估计值=-3.10,SE=1.86;p=0.10。
- 次要生物标志物(脑脊液p-tau181、Aβ40、Aβ42、总tau)所有p值>0.05。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Nicotinamide is a coenzyme involved in cellular oxidation-reduction reactions that can inhibit Class III histone deacetylases (HDACs) or sirtuins. HDAC inhibition can affect numerous therapeutic pathways, including tau phosphorylation. We tested the hypothesis that nicotinamide treatment could reduce tau phosphorylation in early Alzheimer disease (AD). METHODS: We performed a randomized, placebo-controlled, phase 2a proof-of-concept trial to evaluate the safety and tolerability of 48 weeks of treatment with 1,500 mg of nicotinamide twice a day. The primary outcome was level of tau phosphorylated at threonine 231 (p-tau231) in CSF. Prespecified secondary outcomes were levels of p-tau181, total tau, amyloid β40 (Aβ40), and Aβ42 in CSF and the clinical measures Alzheimer's Disease Assessment Scale (ADAS-cog13), Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale-Mild Cognitive Impairment (ADCS-ADL-MCI), and Clinical Dementia Rating Summary of Boxes (CDR-SB). Participants were recruited at 2 academic clinical centers. Enrollment criteria included diagnosis of mild cognitive impairment or mild dementia with CSF biomarker confirmation of AD. The Holm-Bonferroni procedure was used to control type I error within biomarker and clinical domains. RESULTS: Of 47 participants enrolled (mean age = 73.8 years; 43% female), 1 dropped out before treatment initiation and 6 before completion, including 2 in the nicotinamide and 4 in the placebo arm. Adverse events (AEs) were balanced by arm, with few attributed to treatment. Common AEs included infections and nervous system disorders. There was no statistically significant benefit of nicotinamide on the primary outcome of week 48 change from baseline in CSF p-tau231 (analysis of covariance; estimated mean difference in change between arms = -2.06, SE = 4.03; p = 0.61), with observed mean decline in CSF p-tau231 greater in the nicotinamide arm (-4.7 ± 14.5) than in the placebo arm (-2.3 ± 10.6). No significant effects of treatment were observed on secondary biomarker outcomes (CSF p-tau181, Aβ40, Aβ42, and total tau) in similar models (all p values >0.05), with observed mean changes in CSF p-tau181 (0.4 ± 29.8 vs 10.4 ± 41.8) and total tau (8.4 ± 228.6 vs 60.5 ± 237.5) favoring nicotinamide compared with placebo. At week 48, nicotinamide-treated participants experienced less decline on CDR-SB (mixed-effect model with repeated measures; estimate = -1.42, SE = 0.65; p = 0.03 unadjusted for multiple comparisons), without significant differences in cognitive (ADAS-cog; estimate = -1.93, SE = 1.93; p = 0.32) or functional (ADCS-ADL-MCI; estimate = -3.10, SE = 1.86; p = 0.10) outcomes. DISCUSSION: Nicotinamide was safe but did not alter AD biomarkers. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that in patients with MCI or mild dementia with positive CSF AD biomarkers, 48 weeks of nicotinamide, 3,000 mg daily, is no better than placebo in reducing CSF p-tau231. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov: NCT03061474.
引用
- Grill JD, Tam S, Thai G, et al. Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease. Neurology. 2024. PMID: 39671543. doi:10.1212/WNL.0000000000210152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。